Therefore, it remains unclear whether the reduction of steatosis observed in animal and human trials in response to treatment with GLP-1R agonists results from direct activation of hepatic GLP-1R or the indirect impact such as weight loss, increased insulin sensitivity, brain-liver signals such as brain leptin51, or other hormonal signals that these agonists might trigger14. This evidence concerns the gene INS and steatosis.